CLDN18.2

CLDN18.2 CAR-T Therapy Achieves 48-Month Disease Control and Conversion Surgery in Advanced Gastric Cancer With Peritoneal Metastasis

05/08/2026

A remarkable case published in Journal of Hematology & Oncology highlights the potential of satricabtagene autoleucel (CT041), the world’s first approved solid tumor CAR-T therapy, in treating advanced gastric cancer with peritoneal metastasis. After receiving CT041 following first-line therapy, a 53-year-old patient achieved complete disappearance of peritoneal lesions, underwent successful conversion surgery, and maintained disease control for 48 months.

Satri-cel CAR-T Therapy Shows Long-Term Survival Benefits in Advanced Gastric Cancer with Peritoneal Metastasis

03/08/2026

A phase I clinical study published in Journal of Hematology & Oncology reported long-term outcomes of three advanced gastric cancer patients with peritoneal metastasis treated with Satri-cel (Shuricabtagene Autoleucel). Patients achieved durable peritoneal disease control, with the longest follow-up reaching 48 months.

Why people travel abroad to China for stomach cancer treatment

25/07/2026

China has become a leading destination for stomach cancer treatment, offering innovative therapies, experienced specialists, and access to new treatment options that may not yet be widely available elsewhere.

ASCO 2026: Satri-cel Delivers 4.5+ Years of Benefit

Satri-cel demonstrates durable long-term benefit in advanced gastric cancer: ASCO 2026 update

08/07/2026

At ASCO 2026, CARsgen Therapeutics presented more than 4.5 years of follow-up data demonstrating durable responses, prolonged progression-free survival, and a favorable safety profile for Satri-cel (CT041) in advanced gastric and gastroesophageal junction cancer.

Pancreatic Cancer

27/06/2026

Pancreatic cancer is one of the most aggressive solid tumors with limited treatment success. CAR-T cell therapy in China is being actively researched as a new immunotherapy approach, offering potential hope through early-stage clinical trials and innovative engineered T-cell technologies.

Satri-cel (CT041, Kaileimei) Receives NMPA Approval: The World’s First CAR-T Cell Therapy for Solid Tumors

22/06/2026

Satri-cel injection (CT041, Kaileimei®), the world’s first CAR-T cell therapy for solid tumors, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive, HER2-negative advanced

CLDN18.2: A New Beacon of Hope in Pancreatic Cancer Treatment

21/06/2026

CLDN18.2 has become one of the most promising therapeutic targets in pancreatic cancer. From bispecific antibodies and antibody-drug conjugates to CAR-T cell therapy, researchers are exploring innovative approaches that could transform treatment options for patients with this difficult-to-treat disease.

Gastric Cancer: 66.7% Tumor Reduction and Durable 60-Week Complete Remission

08/05/2026

A novel nanobody-based CAR-T therapy targeting Claudin18.2 has demonstrated remarkable efficacy and safety in gastric and gastroesophageal junction cancers, achieving a 66.7% response rate and sustained complete remission beyond 60 weeks in early clinical trials.

First Solid Tumor CAR-T Therapy Enters CSCO Gastric Cancer Guidelines (2026): A Defining Moment for Clinical Practice

30/04/2026

The inclusion of satri-cel in CSCO guidelines signals a major transition of CAR-T therapy from trials to clinical practice in solid tumors.

World’s First: China’s Stomach Cancer CAR-T Therapy Nears Approval with 96% Success

08/03/2025

In a landmark advancement for solid tumor treatment, CARsgen Therapeutics’ CLDN18.2-targeted CAR-T therapy, satri-cel (CT041), has achieved 96.1% disease control rate (DCR) in advanced gastric cancer patients, with plans for a 2025 commercial launch in